Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2013
11/19/2013CA2502636C Diagnosis of shwachman-diamond syndrome
11/19/2013CA2497582C Prophylaxis and treatment of infectious diseases
11/19/2013CA2496213C Metalloprotease activation of myostatin, and methods of modulating myostatin activity
11/19/2013CA2473987C Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
11/19/2013CA2442684C Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
11/19/2013CA2425842C Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia
11/19/2013CA2411694C Furin polypeptides with improved characteristics
11/19/2013CA2404890C Rna sequence-specific mediators of rna interference
11/19/2013CA2398083C Nphs2 gene involved in the cortico-resistant neprhotic syndrome, protein encoded by said gene and diagnostic and therapeutic uses
11/19/2013CA2383217C Lysosomal targeting pathway enzymes
11/19/2013CA2353866C Treatment of papillomavirus infections
11/19/2013CA2346996C Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
11/19/2013CA2329757C Use of .alpha.1.beta.1 integrin receptor inhibitors and tgf-.beta.1 inhibitors in the treatment of kidney disease
11/19/2013CA2305620C Method for the covalent attachment of polysaccharides to protein molecules
11/14/2013WO2013170272A2 Site-specific labeling and targeted delivery of proteins for the treatment of cancer
11/14/2013WO2013170191A1 Methods of using antagonists of nad biosynthesis from nicotinamide
11/14/2013WO2013170147A1 Compounds useful for promoting protein degradation and methods using same
11/14/2013WO2013170146A1 Methods and compositions for modulating mir-204 activity
11/14/2013WO2013170128A1 Use of seaprose to remove bacterial biofilm
11/14/2013WO2013170086A2 Formulations for the delivery of active ingredients
11/14/2013WO2013170077A2 V1a receptor agonists
11/14/2013WO2013170066A1 Peptides for the treatment of cancer
11/14/2013WO2013170022A1 Biofilm prevention, disruption and treatment with bacteriophage lysin
11/14/2013WO2013169913A1 Predictors of patient response to interferon-a therapy
11/14/2013WO2013169693A1 Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
11/14/2013WO2013169616A1 Pharmacokinetic modulation with alisporivir
11/14/2013WO2013169386A1 Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
11/14/2013WO2013169338A1 Ctla-4 variants
11/14/2013WO2013169282A1 Cylodextrin complexation methods for formulating peptide proteasome inhibitors
11/14/2013WO2013169273A1 Synergistic selenopeptide formulations for the protection of dermal papilla cells
11/14/2013WO2013169194A1 Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
11/14/2013WO2013169104A1 Polypeptide mixes with antibacterial activity
11/14/2013WO2013169077A1 Composition for preventing or treating cachexia
11/14/2013WO2013169067A1 Composition for preventing or treating rheumatoid arthritis
11/14/2013WO2013169060A1 Composition for preventing or treating sepsis
11/14/2013WO2013168965A2 Vaccine composition for preventing staphylococcus aureus infection
11/14/2013WO2013168438A1 Protein having lactase activity, gene encoding said protein, recombinant vector carrying said gene, transformant, method for producing said protein, and use of said protein
11/14/2013WO2013168164A1 Variants of tace pro-domain as tnf-a inhibitor and their medical use
11/14/2013WO2013168075A1 Hexadepsipeptide analogues as anticancer compounds
11/14/2013WO2013167842A2 Immunogenic composition comprising a peptide derived from vegf and uses of same
11/14/2013WO2013167750A2 Method for diagnosis and treatment of prolactin associated disorders
11/14/2013WO2013167620A1 Immunomodulatory methods using notch agonists
11/14/2013WO2013167495A1 Bicyclically substituted uracils and the use thereof
11/14/2013WO2013167455A1 Double-acylated glp-1 derivatives
11/14/2013WO2013167454A1 Double-acylated glp-1 derivatives
11/14/2013WO2013167156A1 Transplantation of modified monocytes
11/14/2013WO2013167136A1 Improving adoptive cell therapy with interferon gamma
11/14/2013WO2013166944A1 Rtn4b-related polypeptide, and, preparation and applications thereof
11/14/2013WO2013166943A1 Rtn4b polypeptide, monoclonal antibody thereof, monoclonal antibody-producing hybridoma cell line, and, preparation and application thereof
11/14/2013WO2013166557A1 Methods for treating cachexia
11/14/2013WO2013166555A1 Methods of treating cancer using angiogenin or an angiogenin agonist
11/14/2013WO2013092703A3 Glucagon analogues
11/14/2013WO2012161755A9 Antagonism of the vip signaling pathway
11/14/2013WO2012144912A8 A method of peptide hydrolysis, peptidase, the composition for use as a bacteriostatic and bactericidal agent, a kit and the uses of the active form of lytm from s. aureus or derivatives thereof
11/14/2013WO2012136369A8 Ophthalmic preparations based on pacap (pituitary adenylate cyclase activating polypeptide) which restore the normal visual function in early glaucoma
11/14/2013US20130303592 Treatment of Cancer by Inhibition of IGFBPs and Clusterin
11/14/2013US20130303466 Chemosensory Receptor Ligand-Based Therapies
11/14/2013US20130303465 Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors
11/14/2013US20130303464 Stable ready-to-use cetrorelix injection
11/14/2013US20130303463 Treatment of diseases
11/14/2013US20130303460 Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
11/14/2013US20130303459 Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
11/14/2013US20130303455 Prediction and prevention of preeclampsia
11/14/2013US20130303453 Octreotide injection
11/14/2013US20130303450 Use of somatostatin analogs in meningioma
11/14/2013US20130303449 Surgical applications for bmp binding protein
11/14/2013US20130303448 Therapeutic or Preventive Agent for Diabetes
11/14/2013US20130303443 Novel compounds and their effects on feeding behaviour
11/14/2013US20130303439 Chimeric peptides including a penetrating peptide and a binding domain of pp2a catalytic subunit to caspase-9
11/14/2013US20130303436 Peptide therapeutics and methods for using same
11/14/2013US20130303435 Smart Pro-Drugs of Serine Protease Inhibitors
11/14/2013US20130302806 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
11/14/2013US20130302800 Tumor suppressor gene p47ing3
11/14/2013US20130302795 Cytokine zalpha11 ligand
11/14/2013US20130302448 Phytin aqueous solution and use of said solution for the preparation of a liquid nutritional supplement or a cosmetic composition
11/14/2013US20130302414 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
11/14/2013US20130302412 Transfer Factor Compositions
11/14/2013US20130302411 Agent for use in the case of fructose intolerance
11/14/2013US20130302409 Methods and compositions for cancer immunotherapy
11/14/2013US20130302396 Co-Delivery Of Stimulatory And Inhibitory Factors To Create Temporally Stable And Spatially Restricted Zones
11/14/2013US20130302357 Novel benzodiazepine derivatives
11/14/2013US20130302351 Antagonism of the vip signaling pathway
11/14/2013US20130302344 Methods and medicaments for the treatment of gout or pseudogout
11/14/2013US20130302339 Compositions for diagnosis and therapy of diseases associated with aberrant expression of kremen and or wnt
11/14/2013US20130302332 Method for treating inflammation
11/14/2013US20130302318 Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL
11/14/2013US20130302317 Siglec-9 Binding Agents
11/14/2013US20130302313 Hexon tat-ptd modified adenovirus and uses thereof
11/14/2013US20130302307 Novel Cellular-Factor Containing Solution Compositions
11/14/2013US20130302306 Bacteriophage lysin and antibiotic combinations against gram positive bacteria
11/14/2013US20130302304 Pharmacological vitreolysis
11/14/2013US20130302296 Treatment and Prophylaxis for Obsessive Compulsive Disorder
11/14/2013US20130302291 Compositions and methods for cell transplantation
11/14/2013US20130302281 Stable liquid interferon formulations
11/14/2013US20130302279 Identification of natural plant extracts harboring anti-hepatitis c virus ns5b polymerase activity
11/14/2013US20130302278 Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens
11/14/2013US20130302277 Method of treatment
11/14/2013US20130302274 Combination therapy
11/14/2013US20130302273 Compositions derived from stem cell released molecules & methods for formulation thereof
11/14/2013US20130302272 Therapeutic agents for muscular dystrophy
1 ... 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 ... 3163